Genticel names VP, supervisory board
This article was originally published in Scrip
Genticel, a biopharmaceutical company developing vaccines for patients infected with human papillomavirus, has named Dr Gerald Moeller vice-president of its supervisory board. Prior to joining the Toulouse, France-based firm's board Dr Moeller was an investment adviser at HBM Partners in Switzerland. Dr Moeller chairs the supervisory boards of a number of health sector companies, including 4Sigma, Definien, Invendo-Medical GmbH and MorphoSys. He is also a board member with FIND Foundation and Illumina. Genticel's supervisory board is currently chaired by Professor Thierry Hercend.
You may also be interested in...
In an exclusive interview, Barbara Lueckel, global head of research technologies at Roche Pharma Partnering, talks about the rationale behind the 2020 deals with Bicycle Therapeutics and Nimble Therapeutics. She gives insight into how deal makers are shifting gears to make deals happen in the challenging environment of the global coronavirus pandemic.
As the COVID-19 pandemic escalates, companies across the world are preparing to roll out commercial test kits for the detection of SARS-CoV-2.
Biopharmaceutical companies doubled-down on rare disease treatments during the last five years, thanks to a potent combination of scientific discovery and appealing business incentives.